ALT™
Advanced Lipid Technologies™

    • Advanced Lipid Technologies™ (ALT™)is a collection of unique lipophilic delivery systems capable of by -passing the food effect seen in most lipophilic drug products.
  • ALT™ has been proven to allow lower dosing levels to achieve efficacy.
  • ALT™ allows drug and nutrient absorption in the absence of healthy intestines, bile or normal gastric enzymes

How ALT™ Works

ALT™ is a drug delivery platform that uses proprietary formulation and manufacturing techniques to create products that permit better absorption

    • Does not rely on the presence of food
  • Independent of fat content of food that is present
  • Micelles spontaneously form in the body with no energy required

Comparison of Natural Fat Digestion and Advanced Lipid Technologies ™How Alt Works
ALT™ is a drug delivery platform that uses proprietary formulation and manufacturing techniques to create products that we believe permit consistent absorption of the drug compounds whether or not food is present in the body, and whether food that is present in the body is high or low in fat. We believe ALT™’s mechanism of action has demonstrated the ability to increase the bioavailability of previously insoluble or poorly absorbed compounds, including hormones, omega- 3 ethyl esters, and other lipid- based or lipid- soluble compounds, thereby potentially increasing efficacy and patient compliance.

Our current research suggests that our ALT™ platform will enable us to create for mulations for linically proven substances for approved and new indications that will enhance the bioavailability of the active drug compound,lower the required dosing levels than otherwise required in order to be effective,eliminate any food effects that may inhibit the absorption of the drug compound, and significantly reduce certain side effects associated with other formulations of our active ingredients. We believe our product candidates will onsistently and reliably deliver lipid- based or lipid – soluble compounds, such as eicosapentaenoic acid (EPA), docosahexaenoic acid(DHA)and other omega-3 olyunsaturated fatty acids, into a patient’s bloodstream to address conditions including severe hypertriglyceridemia, liver disease, pancreas-related disease, and SCD.

Google+   Likedin